Aristeia Capital L.L.C. Has $2.34 Million Position in LivaNova PLC $LIVN

Aristeia Capital L.L.C. lowered its holdings in LivaNova PLC (NASDAQ:LIVN) by 26.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 37,985 shares of the company’s stock after selling 13,700 shares during the period. Aristeia Capital L.L.C. owned approximately 0.07% of LivaNova worth $2,337,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Hantz Financial Services Inc. raised its position in LivaNova by 159.9% during the fourth quarter. Hantz Financial Services Inc. now owns 434 shares of the company’s stock valued at $27,000 after buying an additional 267 shares during the period. State of Wyoming acquired a new stake in LivaNova during the 2nd quarter worth about $31,000. Quarry LP purchased a new position in LivaNova during the 3rd quarter valued at about $36,000. EverSource Wealth Advisors LLC increased its holdings in shares of LivaNova by 998.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 703 shares of the company’s stock valued at $32,000 after purchasing an additional 639 shares during the period. Finally, Covestor Ltd increased its holdings in shares of LivaNova by 108.6% in the 4th quarter. Covestor Ltd now owns 753 shares of the company’s stock valued at $46,000 after purchasing an additional 392 shares during the period. Institutional investors and hedge funds own 97.64% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently commented on LIVN. Weiss Ratings upgraded shares of LivaNova from a “sell (d+)” rating to a “hold (c)” rating in a report on Thursday, May 7th. Needham & Company LLC upped their price objective on shares of LivaNova from $64.00 to $81.00 and gave the company a “buy” rating in a research note on Wednesday, February 25th. Robert W. Baird cut their target price on shares of LivaNova from $78.00 to $76.00 and set an “outperform” rating for the company in a research report on Thursday, May 7th. Mizuho boosted their price target on shares of LivaNova from $85.00 to $90.00 and gave the company an “outperform” rating in a report on Thursday, May 7th. Finally, Barclays upped their price target on shares of LivaNova from $73.00 to $76.00 and gave the stock an “equal weight” rating in a research note on Thursday, May 7th. Six research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $79.38.

LivaNova Trading Down 1.2%

NASDAQ:LIVN opened at $78.50 on Thursday. The company has a market capitalization of $4.31 billion, a P/E ratio of 40.26 and a beta of 0.88. The stock’s 50 day moving average price is $70.01 and its 200 day moving average price is $66.14. The company has a debt-to-equity ratio of 0.24, a quick ratio of 1.11 and a current ratio of 1.33. LivaNova PLC has a 52 week low of $41.01 and a 52 week high of $80.96.

LivaNova (NASDAQ:LIVN) last issued its quarterly earnings data on Wednesday, May 6th. The company reported $0.98 EPS for the quarter, beating analysts’ consensus estimates of $0.85 by $0.13. The business had revenue of $362.26 million for the quarter, compared to analyst estimates of $346.05 million. LivaNova had a return on equity of 16.48% and a net margin of 7.48%.The firm’s revenue for the quarter was up 14.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.88 EPS. LivaNova has set its FY 2026 guidance at 4.200-4.300 EPS. On average, research analysts forecast that LivaNova PLC will post 3.73 EPS for the current fiscal year.

Insider Activity

In other news, Director Francesco Bianchi sold 1,800 shares of LivaNova stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $75.75, for a total value of $136,350.00. Following the transaction, the director directly owned 7,228 shares in the company, valued at approximately $547,521. The trade was a 19.94% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.35% of the company’s stock.

LivaNova Company Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.